Syrma SGS Technology Ltd

- The company has board and stakeholder approval for a Qualified Institutional Placement (QIP) but has not initiated it yet; it will only be considered for future growth opportunities, not for existing business working capital needs. - The management emphasizes that equity raising is the costliest form of funding and will only be done if a compelling opportunity arises. - Currently, there is enough internal accrual to sustain continuous growth without external equity. - No current plans for QIP specifically for existing business; any equity raise would be related to inorganic growth or new ventures like OSAT, pending strategy clarity. - On debt, the company’s gross debt is about Rs. 685 crore with Rs. 412 crore in treasury (net debt Rs. 273 crore), primarily working capital funded. - Continuous efforts are on to reduce working capital days below 60. - Capex of Rs. 180 crore spent this year on new facilities; future expansion may require additional capital but no explicit new debt fundraising announced yet.

- Current FY 2025 capex: Around Rs. 200 to 245 crore, with an expected spend of Rs. 32 crore in the current quarter (Page 20). - FY 2026 capex: Expected to be around Rs. 100 to 150 crore (Page 20). - Capex primarily towards new campus facility in Pune and a facility in Germany, plus SMT lines and plant & machinery for new customer onboarding (Page 6, 20). - The Pune facility is recently set up; expansion there can be done reasonably quickly to increase capacity for FY 2026-27 (Page 20). - Company evaluating inorganic acquisitions, focusing on design, defense, and other technology-access areas; no deal finalized yet (Page 25). - Considering possible near-shoring to the USA depending on policy developments, which may require strategic capex or acquisitions (Page 25). - QIP approval is in place as a contingency for future growth or acquisitions, but no current plans to raise equity (Page 24-25). These investments align with building sustainable, long-term organizational growth.

- The company expects to achieve industry-beating growth of 30-35% in FY '26, continuing momentum from previous quarters. - Revenue guidance for FY '25 stands around 4,200-4,500 crores, with potential for marginal variation; target EBITDA margins of 7%+ remain intact. - Industrial and automotive segments are growing, with a rising share in the order book; industrial segment expected to expand due to new clients and exports. - Railways revenue targeted at around 100 crores in FY '26, up from 70 crores in FY '25, driven by new product approvals. - MedTech business is anticipated to rebound with accelerated growth post-FY '26, contributing a reasonable chunk of revenue by FY '26-'27. - Exports are targeted to recover and increase back to 25-30% of revenues from current ~20%, especially with the commissioning of Germany facility. - Capacity utilization is around 70%, capable of scaling to ~4,000 crores revenue with new facilities like Pune ramping up. - High-volume consumer business targeted to reduce to ~35%, enhancing overall margins and growth quality.

- FY '25 EBITDA margin guidance is 7%, targeting approximately ₹305-310 crore EBITDA, with confidence in achieving this. - FY '26 expected growth of 30-35% in revenues, with a corresponding increase in EBITDA margins due to operational leverage. - Management aims to reduce high-volume, low-margin consumer business to below 35% of revenue to improve overall margins. - Industrial, automotive, railway, and other segments expected to contribute higher-margin businesses and revenue growth. - Railways revenue targeted to grow from ₹70 crore in FY '25 to around ₹100 crore+ in FY '26 (approx. 50% growth). - MedTech business anticipated to rebound and grow significantly from FY '26 onwards. - Export business targeted to increase to 25-30% of revenue over the long term, contributing to higher margins. - ROCE is expected to improve, targeting 14.5-15% this year and moving toward 18-20% by FY '27. - The company focuses on consistent EBITDA growth rather than just revenue growth, with strategic emphasis on margin improvement.

- As of December 2024, Syrma SGS Technology Limited's open order book visibility is approximately INR 5,300 crores. - The order book composition includes: - Over 30% contribution from the auto segment. - Around 38-40% from the consumer segment. - Approximately 20-22% from the industrial segment. - The remaining portion from healthcare, IT, and railway segments. - Orders are typically executed over a period of 9 to 15 months. - The company has decent order intake in the recent quarter with a solid long-term order book. - For the railway segment, the company targets INR 70 crores revenue for the current year and aims for a 50% growth next year (around INR 100 crores+). - MedTech segment holds approximately 7-7.5% of total order book visibility; expected to ramp up significantly in FY 26-27. - New product approvals, especially in railway and MedTech, are in pipeline, indicating future order growth.